In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Avandia and the Commercial Impact of FDA's Credibility Gap

Executive Summary

GlaxoSmithKline's diabetes drug Avandia survived a perilous FDA advisory committee review. The real question is whether the industry can survive the damage to FDA's credibility.

Related Content

Biopharma: Reviewing 2007 to Forecast 2008
FDA Fast Talk: Health Advisories with Unclear Advice
Start-Up Previews (07/2007)
Not the Usual Suspects: FDA Seeks New Advisors for Risk Communication Committee
The Race for Avandia's Share: May the Safest Product Win
Start-Up Previews (07/2007)
The Death of Arcoxia: Drug Regulation in a "Whistleblower" Climate
The Agency that Cries Wolf
Shadow FDA? Researchers Are Taking Approval Matters into their Own Hands


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts